NEWS
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher tissue exposure and lower systemic concentrations compared to conventional oral administration.
Key findings include:
Colon tissue drug levels above IC50 at 24 hours post-dosing
Projected tissue levels above IC90 through at least 16 hours after 5 mg or 10 mg doses
Pan-colonic delivery achieved with evidence of drug exposure in distal colon
Lower systemic drug exposure, potentially reducing toxicity risks
NaviCap devices were well-tolerated with no early release and >95% colon entry detection
These results support BT-600's potential to improve ulcerative colitis treatment efficacy and validate the NaviCap platform for targeted GI drug delivery.
Key findings include:
Colon tissue drug levels above IC50 at 24 hours post-dosing
Projected tissue levels above IC90 through at least 16 hours after 5 mg or 10 mg doses
Pan-colonic delivery achieved with evidence of drug exposure in distal colon
Lower systemic drug exposure, potentially reducing toxicity risks
NaviCap devices were well-tolerated with no early release and >95% colon entry detection
These results support BT-600's potential to improve ulcerative colitis treatment efficacy and validate the NaviCap platform for targeted GI drug delivery.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2310Followers
105Following
24KVisitors
Follow